Management of disseminated disease in the patient with bladder cancer.
Advanced transitional cell carcinoma of the bladder is a chemotherapy-sensitive neoplasm. Several single agents demonstrate substantial activity, and combination chemotherapy produces responses in the majority of patients treated. The benefits and toxicities associated with the most widely used combination regimens are discussed. Other topics reviewed include the use of colony-stimulating factor support for chemotherapy, adjunctive surgical therapy, and newer cytotoxic regimens.
Department of Internal Medicine, Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, North Carolina.
J J
JJ
Perry
H B
HB
Muss
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
D000970:Antineoplastic Agents